ALLK Stock Overview
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases.
Allakos Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.14|
|52 Week High||US$86.95|
|52 Week Low||US$2.54|
|1 Month Change||35.89%|
|3 Month Change||90.19%|
|1 Year Change||-88.50%|
|3 Year Change||-93.28%|
|5 Year Change||n/a|
|Change since IPO||-73.95%|
Recent News & Updates
Allakos: Potential For Comeback With Lirentelimab With 2 IndicationsOct 18
Allakos prices ~$150M underwritten offeringSep 19
Allakos (NASDAQ:ALLK) Will Have To Spend Its Cash WiselyAug 06
Will Allakos (NASDAQ:ALLK) Spend Its Cash Wisely?Apr 22
We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash WiselyDec 01
We Think Allakos (NASDAQ:ALLK) Can Afford To Drive Business GrowthAug 16
We're Hopeful That Allakos (NASDAQ:ALLK) Will Use Its Cash WiselyMay 02
Have Allakos Inc. (NASDAQ:ALLK) Insiders Been Selling Their Stock?Mar 10
Allakos Inc. (NASDAQ:ALLK) Insiders Have Been SellingJan 28
We're Interested To See How Allakos (NASDAQ:ALLK) Uses Its Cash Hoard To GrowDec 07
|ALLK||US Biotechs||US Market|
Return vs Industry: ALLK underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: ALLK underperformed the US Market which returned -14.9% over the past year.
|ALLK Average Weekly Movement||13.2%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: ALLK is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: ALLK's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases.
Allakos Inc. Fundamentals Summary
|ALLK fundamental statistics|
Is ALLK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALLK income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-4.36|
|Net Profit Margin||0.00%|
How did ALLK perform over the long term?See historical performance and comparison